CBLB 612

Drug Profile

CBLB 612

Alternative Names: CBLB-612

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Cleveland BioLabs
  • Class Chemoprotectants; Proteins
  • Mechanism of Action Haematopoietic system modulators; Stem cell modulators; Toll like receptor 2 agonists; Toll like receptor 6 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stem cell mobilisation

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 19 Jul 2016 Cleveland BioLabs completes its phase II trial for Stem cell mobilisation (Treatment experienced, Prevention) in Russia (NCT02778763)
  • 16 May 2016 Cleveland BioLabs completes enrolment in its phase II trial for Stem cell mobilisation (Treatment experienced, Prevention) in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top